Fatigue News and Research

RSS

Sleep duration naturally waxes and wanes according to researchers at University of Sydney

There’s no need to panic if you didn’t get a solid eight hours of beauty sleep last night. According to new University of Sydney research, sleep duration naturally waxes and wanes over a period of days regardless of individual lifestyle, timing of sleep or waking, and social and environmental influences.

29 Jan 2013

Devex interviews WHO NTD department director on roadmap for eliminating 17 diseases

"Lorenzo Savioli, director of WHO's department of neglected tropical diseases, spoke to Devex from Geneva in a phone interview on Wednesday, January 23, days after WHO released a progress report on its year-old roadmap to eliminate 17 tropical diseases," Devex's "Development Newswire" blog reports.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Qigong reduces depressive symptoms and improves QOL in women with breast cancer

Researchers from The University of Texas MD Anderson Cancer Center have found qigong, an ancient mind-body practice, reduces depressive symptoms and improves quality of life in women undergoing radiotherapy for breast cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Effective therapy needed for chronic fatigue syndrome patients

Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Simulation ticks box for checklists in surgical care

The management of operating-room crises could be significantly improved by using checklists, say researchers in the New England Journal of Medicine.

22 Jan 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

NSU to host conference on neuro immune conditions

Nova Southeastern University (NSU) will be hosting a conference on Saturday, Jan. 26 about the upcoming opening of the NSU College of Osteopathic Medicine's Institute for Neuro Immune Medicine.

19 Jan 2013

Study examines consequences of muscle activity with surprising results

A study in The Journal of General Physiology examines the consequences of muscle activity with surprising results, indicating that the extracellular accumulation of potassium that occurs in working muscles is considerably higher than previously thought.

18 Jan 2013

Burnout can cause negative health effects in middle-aged working women

Emotional exhaustion and physical and cognitive fatigue are signs of burnout, often caused by prolonged exposure to stress. Burnout can cause negative health effects including poor sleep, depression, anxiety, and cardiovascular and immune disorders.

18 Jan 2013

Tips to help maintain health during travel

Whether you're away for business or pleasure, don't let traveling be an excuse to break your healthy New Year's resolutions. Check out these tips from Jodi Sullivan, Hilton Worldwide's senior director of global fitness, to help maintain your health wherever your travels may take you.

18 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013

Tamoxifen can counteract some pathologic features in mouse model of DMD

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.

16 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013